Celldex Therapeutics (NASDAQ:CLDX – Free Report) had its target price lifted by Morgan Stanley from $50.00 to $57.00 in a research report released on Wednesday morning,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. Other equities research analysts have also recently issued research reports about the company. Canaccord Genuity Group dropped […]

Celldex Therapeutics (NASDAQ:CLDX – Free Report) had its price target boosted by Cantor Fitzgerald from $61.00 to $72.00 in a research report released on Tuesday,Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the biopharmaceutical company’s stock. A number of other analysts have also issued reports on CLDX. Barclays lifted their price objective on […]

Compass Therapeutics (NASDAQ:CMPX – Get Free Report) had its target price reduced by research analysts at Citizens Jmp to $4.00 in a research report issued on Wednesday, Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp’s price objective indicates a potential upside of 222.58% from the stock’s current price. […]

Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) had its price objective hoisted by investment analysts at Leerink Partners from $70.00 to $88.00 in a research report issued on Wednesday, Benzinga reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Leerink Partners’ price target suggests a potential upside of 162.61% from the […]

Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) had its price objective boosted by analysts at Morgan Stanley from $50.00 to $57.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price target would indicate a potential upside of 70.10% […]

Edgewise Therapeutics (NASDAQ:EWTX – Free Report) had its target price increased by HC Wainwright from $45.00 to $57.00 in a report issued on Monday, MarketBeat Ratings reports. HC Wainwright currently has a buy rating on the stock. A number of other equities research analysts also recently weighed in on the stock. Wall Street Zen raised […]

Cullinan Therapeutics (NASDAQ:CGEM – Free Report) had its target price lifted by BTIG Research from $39.00 to $40.00 in a research report sent to investors on Monday morning, Marketbeat reports. BTIG Research currently has a buy rating on the stock. Other equities research analysts have also recently issued research reports about the stock. Wall Street […]

Definium Therapeutics (NASDAQ:DFTX – Get Free Report) had its target price upped by investment analysts at Robert W. Baird from $75.00 to $79.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s price objective would suggest a potential […]

Spero Therapeutics (NASDAQ:SPRO – Get Free Report) had its price objective upped by research analysts at HC Wainwright from $5.00 to $6.00 in a research note issued to investors on Monday, Marketbeat.com reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 430.97% from […]

Ovid Therapeutics (NASDAQ:OVID – Free Report) had its price objective increased by HC Wainwright from $4.00 to $5.00 in a report released on Friday, Marketbeat.com reports. They currently have a buy rating on the stock. A number of other equities analysts have also weighed in on the company. Roth Capital reiterated a “buy” rating and […]

BridgeBio Oncology Therapeutics (NASDAQ:BBOT – Free Report) had its target price decreased by Leerink Partners to $27.00 in a research note released on Thursday,Benzinga reports. Leerink Partners currently has an outperform rating on the stock. A number of other research firms have also recently commented on BBOT. Weiss Ratings restated a “sell (d-)” rating on […]